Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-23

Clinical Trial Update: A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating onabotulinumtoxinA (Botox) for social anxiety disorder was terminated, and results were posted in January 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Botox (OnabotulinumtoxinA)

Snippet

Sponsor: Daniel Lieberman | Conditions: Anxiety Disorder Social, Anxiety | Phase 4 | Status: TERMINATED | Results posted: 2019-01-23